Reneuron Share Discussion Threads

[supernumerary] 16/12/2019 17:54

Gone, or just moved?

[diversification] 16/12/2019 17:11

A very positive announcement today as the overhang has now gone.

[investordave] 16/12/2019 15:59

Look at all the sellers rushing out to bank enough money for their weekly shops. Why bother offloading at this price?

[brad_k] 16/12/2019 15:45

So Schroder notification of 16.58% holding is just a result of them taking over Woodford PCT stock yes?
Currently Reneuron site is showing Schroder and Link Funds with over 16% each, so I am not sure anything has really happened. Have I missed something or is the current leap in the share price a misunderstanding of why Schroder are notifying?
Personally I would be very pleased if Schroder chose to keep the holding in the medium term.

[investordave] 16/12/2019 11:50

Lots of buys today yet the share price has not changed. Looks like there may have been a largish sell in the background which is now being used to meet small buy orders.

[dickbush] 12/12/2019 12:55

Well, so much for charts. Today we are down to a new low post the Woodford fiasco, and it seems that very little volume is needed to knock the share price. It looks like we may have to suffer more weakness until the overhang of Woodford's holding is redistributed. This, apparently, will be no earlier than the end of January. The Chairman (80,000 bought at 225p) must be feeling even sicker than I am.

[dickbush] 11/12/2019 12:53

Recent interview on YouTube

[edmonda] 09/12/2019 10:43

last week's interims from reported the pleasing combination of encouraging early trial reports, a healthy cash balance (£21.3m at y/e), and the tie-up with leading Chinese player Fosun Pharma.

New research note from Equity Development out and freely accessible here:

[dickbush] 09/12/2019 09:13

Thanks, Skipper. Interesting list of shareholders. Walker Crips? It's not a typo.

[the skipper] 08/12/2019 23:20

According to the FT tearsheets Woodford was down to 16.58% by 15th October. LFS was up to 16.42% by the same date.

[hashertu] 08/12/2019 16:36

Just quoting IC.
At the bottom of the table, it says:
"Source companies Capital IQ, Investigate, Bloomberg, accurate as at 21 Nov 2019".

Note, also, that the RENE shares did not go to Blackrock.

[dickbush] 08/12/2019 16:25

I'm open to correction but after selling a bit I understood his funds were down to a total of circa 33%. He was given a special dispensation to go to circa 35% through the issue at £5 in 2015.

Is it really over four years ago that this was £6?.

[hashertu] 08/12/2019 10:50

Abstracted from Friday IC

Woodford/Link Fund Solution shareholding in RENE

31/5/19 WIM 35.4%
21/11/19 LFS 16.4%

The difference has been sold.
Some way to go, unfortunately.

[dickbush] 06/12/2019 11:27

I'm no chartist but after going sideways to slightly up since October, the price has now moved above the 50 day weighted moving average. The unweighted 50 day moving average is circa 144p. With no news coming that is likely to be bad, and a couple of significant positives (a deal, Woodford's holding) in the offing, I've added this morning.

[volsung] 06/12/2019 10:59

Looks like a triple bottom chartwise

[dickbush] 06/12/2019 10:42

From the webcast:

Following a protocol amendment next year a further 6 to 12 patients will be added to the RPC trial. Hoping to move straight to a phase 3 trial after results of the 2a trial. Patients would have both eyes treated and the control group would have no treatment. To avoid surgical related incidents, patients with very poor retinas unlikely to be treated.

Moving to 2/3rds of patients being treated in the stroke trials. They were losing patients from the trial because the 50:50 odds were deemed too low.

[dickbush] 06/12/2019 09:09

Napoleon 14th. The cash burn of £5.15 mil was for one half, a period when they received a net £5.4 mil from Fosun. Without another Fosun payment they would have zero cash by September 30th 2020 and that's not even taking into account the major increase in spending required for a much greater number of patients in the CTX trial.
The company needs money, probably a lot of it. The guy who was hired some six months ago to do Fosun-like deals needs to start earning his salary. With a deal or deals the share price should appreciate mightily, particularly once Woodford's shares are distributed. But the higher they go, the more certain is a placing or rights issue IMO.

[lauders] 06/12/2019 08:37

"In the months ahead" is rather open-ended though. Anyone could interpret that to mean years ahead as months lead to years. Will hold and possibly top-up on any major weakness, but in hindsight should have sold in the 300p area and bought back. If only I was a trader!

[stevedd] 06/12/2019 08:26

The best part for me was "We hope to be able to announce further deals with commercial third parties across our various programmes in the months ahead." They must be reasonably confident in this to state a time frame. Any further deals will provide a real confidence boost in the products and the progress they are making.

[napoleon 14th] 06/12/2019 08:24

Looks OK.
Cash = £21.3M, 2019 cashburn = £5.15M, so basically we have 4 years before
needing funds, in the absence of any further progress in financial performance.
Progress depends on scientific performance and saleability, about which I can only
take the experts' words as I know nothing, like Manuel...

Needs to get the Woodford factor done and dusted.
I'll keep what shares I have here, reduced to a free carry.
Might even add some if the chart looks positive.

[bonzo] 06/12/2019 08:23

Perhaps we will now see the share price move back to more sensible levels.

[volsung] 06/12/2019 08:15

Bought back in at 137p

[ayl30] 06/12/2019 07:40

Rns reads well, all going well it seems